PDCD1 and hepatocellular carcinoma: reported that HCC patients receiving PD‐1 inhibitors combined with intensity‐modulated radiotherapy and antiangiogenic therapy showed better outcomes when baseline PD‐L1+ CTCs were <2, with higher objective response rate (56 .5% vs.